

# THE ROLE OF SKIN MICROBIOME IN THE PATHOGENESIS OF ACNE VULGARIS

CRISTIANA STOICA\*, CĂLIN GIURCĂNEANU\*\*, LILIANA GABRIELA POPA\*\*,  
CRISTINA BEIU\*\*, ANA ION\*, ALEXANDRA DOROBANȚU\*, OLGUȚA ANCA ORZAN\*\*,  
MARA MĂDĂLINA MIHAI\*\*

## Summary

*Acne vulgaris is a highly prevalent inflammatory disease, which affects predominantly young adults. The infectious factor, along with the hypersecretion of sebum with altered lipid composition, the abnormal proliferation and differentiation of keratinocytes in the hair follicle, as well as the inflammasome activation with the infiltration of immune cells into the perifollicular dermis are considered to play an essential part in the pathophysiology of acne vulgaris. It has been shown that Cutibacterium acnes is the most prevalent and abundant bacterial species on the skin with the highest presence in sebaceous gland-rich skin. Furthermore, Cutibacterium acnes has many interactions with key events involved in the pathogenesis of acne, including: host inflammation, augmentation of lipogenesis, comedo formation and biofilm production. This article's purpose is to emphasize the correlations between the skin microbiome and acne vulgaris by describing the complex effects that Cutibacterium acnes and other bacterial species exert on the sebaceous follicle.*

**Keywords:** acne vulgaris, skin microbiome, Cuti-bacterium acnes, Staphylococcus epidermidis.

Received: 7.11.2020

Accepted: 7.12.2020

## Introduction

The number of microbial cells that colonize the human body is ten times higher than the number of human cells and it is estimated that the microbes of the skin and gut are vital to the metabolic, hormonal, and immunologic equilibrium of the host [1, 2, 3].

The term 'microbiome' refers to a multitude of microorganisms, including viruses, bacteria and fungi, but also their metabolites, genes and the environment surrounding them [1, 2, 3]. The term 'microbiota' is more limited, describing the group of commensals and symbiotic microorganisms, but also the pathogenic ones found in a fixed environment [1, 2, 3].

Host-microbiome interplay is frequently involved in the pathogenesis of chronic dermatologic diseases such as acne vulgaris, rosacea,

hidradenitis suppurativa, atopic dermatitis, psoriasis vulgaris, chronic wounds and many others [4, 5, 6, 7, 8, 9].

Acne vulgaris is a highly prevalent inflammatory disease of the human sebaceous follicle, that affects approximately 85% of young adults [10]. Four important factors have been thought to contribute to the pathogenesis of acne: the hypersecretion of sebum with altered lipid composition, the abnormal proliferation and differentiation of keratinocytes in the hair follicle leading to comedogenesis, the infectious factor with the implication of *Cutibacterium acnes* (*C. acnes*) and other microorganisms, as well as the inflammasome activation with the infiltration of immune cells into the perifollicular dermis [10]. These pathogenic factors are expressed in unique proportions for each individual affected by acne vulgaris. Moreover, the factors influence each

\* Clinic of Dermatology and Allergology, "Elias" Emergency University Hospital, Bucharest, Romania.

\*\* Department of Oncologic Dermatology, "Elias" Emergency University Hospital, „Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania.

other producing complex vicious circuits. The host- microbiome interplay in acne vulgaris is essential in the pathogenesis and it is best reflected by the results of advanced molecular studies. There were observed significant differences of the microbiomes in inflammatory and non-inflammatory lesions, regarding bacterial diversity and activity [5].

The infectious pathogenesis of acne vulgaris was intensely debated over the past few years. There were described two types of skin microbiome: the resident microbiome and the transient one. The resident microbiome consists of commensal microbes that live in homeostasis with the host and includes *C. acnes* and *Staphylococcus epidermidis* [11]. The transient microbiome consists of pathogen microbes from the environment, which temporarily live on the skin and includes *Staphylococcus aureus* [11]. It has been suggested that a microbial imbalance or dysbiosis compared with the normal distribution in healthy tissues, is involved in the pathophysiology of inflammatory acne [11].

All the complex concepts and controversies have led us to perform a literature review on the role of skin microbiome in the pathogenesis of acne vulgaris.

## The skin microbiome

The skin is the human body's largest organ, colonized by a heterogenous communities of microorganisms, including bacteria, fungi, viruses, most of which are harmless or even beneficial to their host. Innate and adaptive cutaneous immune responses can modulate the skin microbiota, but the microbiota also functions in educating the immune system [4].

Bacteria represent the most dominant members of the cutaneous microbiome. More than 40 bacterial types have been identified on the skin, mainly belonging to: Actinobacteria (Corynebacterineae, Propionibacterineae), Firmicutes (Staphylococcaceae), Proteobacteria and Bacteroidetes [12, 13, 14].

The proportions of these bacteria vary depending on individuals, body sites, as well as skin micro-environments. Environmental factors such as temperature, occupation, ultraviolet radiation exposure, humidity or the use of

antibiotics, soaps, cosmetics can influence microbial colonization of the skin [15, 16, 17].

The microbial density and composition also change with age. In neonates, the microbiota depends on the route of delivery, and in infancy, dominant is Firmicutes [18]. The microbiota of the sebaceous sites is formed during puberty when hormonal changes activate the sebaceous glands [19]. The bacterial composition and diversity is also influenced by gender so women's hand surfaces carry a more diverse set of microorganisms than men's [20].

Skin sites are divided into three categories: moist areas (sole, popliteal fossa, axillae, inguinal area), dry sites (forearm), and sebaceous sites (head - especially on the forehead, nasal and alar crease, retro-auricular; upper trunk; genital) [3, 4]. The bacteria especially found in moist area are *Staphylococcus* and *Corynebacterium* spp. [3,4]. Dry skin sites present in various proportions the four major phyla- Actinobacteria, Firmicutes, Proteobacteria and Bacteroidetes [3,4]. Sebaceous sites have the lowest bacterial diversity because few microorganisms can tolerate the environment. *Cutibacterium* spp. can survive in anaerobic, lipid-rich conditions and are the main isolates from sebaceous areas [3,4].

Sebaceous follicles are the target for acne. The microbiome of the pilosebaceous units is similar with the surface composition and comprises two major residents namely *C. acnes* and *Staphylococcus epidermidis*, but it can comprise in variable quantities other *Cutibacterium* spp. like *C. granulosum* and *C. avidum*, as well as species belonging to *Staphylococcus*, *Corynebacterium*, *Pseudomonas* and the commensal fungi *Malassezia* [21, 22]. These microbes have the ability to form communities known as biofilms. In the pilosebaceous follicle, a biofilm matrix can act as a biological adhesive to restrict sebum passage into the infundibulum and promotes retention and accumulation of corneocytes in the lumen, resulting in a keratinaceous plug and leading to comedo formation [21, 22].

### *Cutibacterium acnes*

In 1896, *C. acnes* was first described by Paul Gerson Unna when observing histological sections of comedones and was initially named as *Bacillus acnes*; later, in 1922 was first classified in

the genus *Corynebacterium* and in 1933 the name was changed again in *Propionibacterium acnes*. In 2016, metagenomics and genomic investigations resulted in new reclassification of *P. acnes* into *Cutibacterium acnes*, but frequently the name of *P. acnes* continues to be used to reduce the confusion between *Cutibacterium* and *Corynebacterium* [10, 23, 24]. In this article the new nomenclature of *Cutibacterium acnes* (*C.acnes*) will be used.

*C. acnes* is involved in key events of acne pathogenesis, including: host inflammation, augmentation of lipogenesis, comedo formation, biofilm production. Recently, studies using the latest molecular methods show that imbalance between the multitude of skin microorganisms and different strains of *C. acnes*. The development of acne as well as its severity may be associated with a loss of diversity of *C. acnes* strains compared with healthy individuals [ 25, 26, 27].

*C. acnes* is the most prevalent and abundant bacterial species on the skin with the highest presence in sebaceous gland-rich skin [10].

In the study of Leyden JJ *et al.*, the facial and scalp skin contained the highest density of *C. acnes* ( $\sim 10^{5-10^6}/\text{cm}^2$ ), followed by the torso and upper limbs, and the lowest density of *C. acnes* is at the lower limbs ( $\sim 10^2/\text{cm}^2$ ) [28]. The density of *C. acnes* also varies with age, so it is very low on the skin of children before puberty, but increases with age-from adolescence to adulthood, and then decreases after the age of 50 years [28, 29, 30].

*C. acnes* is also an important skin commensal. It hydrolyses triglycerides, releases free fatty acids and maintains low skin pH. The low skin pH inhibits the colonization of pathogenic bacteria, such as *Streptococcus* and *Staphylococcus aureus* [4, 31, 32].

Studies have reported that certain strains of *C. acnes* express linoleic isomerase, leading to an increase in trans-10, cis-12 conjugated linoleic acid [33, 34, 35, 36]. This activation of lipid mediators could trigger endoplasmic reticulum stress (and subsequent apoptosis), thus contributing to the pathogenesis of acne lesions. This led to the hypothesis that the replacement of *C. acnes* strains related to the inflammatory process in acne skin with those strains that are not associated with inflammation, might reduce the

degree of acne [33, 34, 35, 36]. A study published in 2019 showed that this replacement led to a significant reduction in non-inflamed lesions [36].

*C. acnes* classification based on genetic variations includes three major genetic phylotypes I, II, and III [10, 23]. Based on multilocus sequence typing, *C. acnes* was subdivided into phylogenetic classes IA-1, IA-2, IB-1, IB-2, IB-3, IC, II, and III [10, 23]. Moreover, *C. acnes* strains have been classified by 16S rRNA gene sequencing into ten major ribotypes [10, 23]. These classifications are very useful, since they facilitate the study of correlations between particular *C. acnes* strains and disease activity [23]. Strains IA-2, IB-1 and IC seem to be associated with acne [3, 14, 23, 37, 38] while strain II is more frequent in healthy skin [3, 14, 23, 37, 38]. Strains IA-1, IB-2, and IB-3 were identified in both [14, 23, 3, 37, 38]. Type III strains are rarely present on the face and more abundant on the back, being associated with the condition of progressive macular hypomelanosis [23, 39, 40].

RT1, RT2 and RT3 were found in both healthy and acne individuals with no significant differences [10]. RT4, RT5 and RT8 were found in acne patients, while RT6 was found mostly in healthy individuals [10].

### 1. Host inflammation

*C. acnes* activates the innate immunity, interacting with Toll-like receptors (TLRs), TLR-2 in particular, protease-activated receptors (PARs), antimicrobial peptides (AMPs), and matrix metalloproteinases (MMP) [41,42]. It upregulates the production and secretion by human sebocytes, keratinocytes and macrophages of pro-inflammatory cytokines, including IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, IL-8, IL-12, TNF- $\alpha$  (tumor necrosis factor alpha), GM-CSF (granulocyte-macrophage colony-stimulating factor),  $\beta$ -defensin, interferon and other polypeptides, thereby initiating and/or exacerbating inflammatory responses [41, 42].

*C. acnes* also activates the two pathways of the complement: classical and alternative pathways, with the increase in C3a and C5a, leading to vascular permeability and lymphocyte infiltration [43, 44].

*C. acnes* is able to modulate keratinocyte differentiation by inducing  $\alpha 3$ ,  $\beta 1$ ,  $\alpha 6s$ , filaggrin and  $\alpha V\beta 6$  integrin expression on keratinocytes, changes observed in the development of acne lesions [45]. *In vitro* studies have shown that *C. acnes* can induce the stimulation of T cells (Th1/Th17) and the production of IL-17 [46]. CD3<sup>+</sup> cells were identified near *C. acnes*-positive comedones, cells that were absent from the surrounding inflamed lesions of acne [47]. These findings support the role of *C. acnes* in the initiation of inflammation in acne vulgaris [47].

On the other side, *C. acnes* also induces the secretion of staphylococcal lipoteichoic acid which could reduce the inflammation by inhibiting TLR-2 expression in keratinocytes and inducing expression of miR-143 [48, 49].

*C. acnes* produces multiple enzymes (proteases, lipases, phosphatases, porphyrins, hyaluronidases), while it is also able to activate host cells to produce matrix metalloproteinases (MMPs) [50, 51, 52]. Therefore, the microorganisms injure sebaceous glands, hair follicles and the dermal extracellular matrix and exacerbate inflammation [50, 51, 52].

A recent study reported that *C. acnes* can produce a pore forming toxin, the CAMP factor (Christie-Atkinson-Munch-Peterson factor), that induces sebocyte death, resulting in an amplified inflammation of the sebaceous glands [53, 54]. In addition, another study reported that CAMP factor 1 of *C. acnes* stimulated keratinocytes *in vitro* by direct interaction with TLR-2 [55].

*C. acnes* also secretes porphyrins that can generate reactive oxygen species and can induce keratinocyte inflammation [56]. In addition to these findings, a study from 2013 by McDowell *et al.* suggested that a CAMP – factor targeted therapy could be the subject of future research in order to establish what may be its exerted effect on *C. acnes* strains [54].

Hyaluronidase is an enzyme with two variants in the *C. acnes* population that differ in their ability to degrade hyaluronic acid and could be involved in the pro-inflammatory responses observed in acne [57]. First variant is observed in *C. acnes* type IA strains and can be associated

with acne, while the second variant was identified in *C. acnes* type IB and II strains and is associated especially with soft tissue infections. [57] HA fragments interact with CD44 or TLR-2 and can induce the inflammatory response [57].

Lipase is a *C. acnes* virulence factor that causes increased amounts of short chain fatty acids, especially free oleate, which promotes the adhesion of *C. acnes* and initiates biofilm formation [10].

Zouboulis *et al.* (2019) showed that short-chain fatty acids (SCFAs) produced by *C. acnes* in hypoxic, lipid-rich conditions have a pro-inflammatory effect on keratinocytes [58]. These short-chain fatty acids are shown to influence the behaviour of sebocytes and keratinocytes through two mechanisms: the inhibition of histone deacetylase activity and the activation of fatty acid receptors [58]. Epidermal keratinocytes express more proinflammatory genes, breaking the epithelial tolerance to these commensal microorganisms [31, 58].

## 2. Augmentation of lipogenesis

Moreover, *C. acnes* has been involved in lipogenesis, as it stimulates the sebaceous glands through the corticotropin-releasing hormone pathway [59]. CRH expression has been described in acne; a study of facial skin biopsies of patients diagnosed with acne reported a higher expression of CRH in sebocytes of affected skin compared with normal skin [60]. CRH increases sebaceous lipid synthesis and induces IL-6 release and IL-8 release by sebocytes, mediated by the CRH receptor [61].

## 3. Comedogenesis

An essential factor in the pathogenesis of acne is abnormal follicular keratinization with exacerbated proliferation of acroinfundibular keratinocytes that promote comedones [10]. The most important comedogenic factors are free fatty acids. They are released from sebum triacylglycerols by the action of *C. acnes* lipase [10]. Some studies have also found that interleukin-1 $\alpha$  (IL-1 $\alpha$ ), which has been detected in open comedones, plays an important role in

comedogenesis [10]. Free oleic acid improves calcium influx into epidermal keratinocytes. Increases keratinocyte proliferation and induces abnormal keratinization associated with increased IL-1 $\alpha$  release [10]. Free palmitic acid acts as a stimulating ligand of TLR-2 and activates the NLRP3 inflammasome [10]. Free palmitic acid, oleic acid, and DAGs (diacylglycerols) act as danger signals that activate the innate immune response [10].

#### 4. Biofilm production

Another pathological feature of *C. acnes* is the ability to develop biofilms, protecting themselves from the host's immune system, antimicrobials or other environmental factors [3, 37]. Microorganisms attach to a surface, multiply and produce an extracellular protective matrix, a process regulated by bacterial signalling through *quorum sensing* [10]. While in comedones there were described biofilms of *C. acnes* in a proportion of 16%, in active acne lesions biofilms were present in 86% of cases [62, 63].

### Other acne vulgaris-associated microorganisms

Several other bacteria colonize the surface of the skin, some of which are important in maintaining skin health, while others can exacerbate certain diseases [23].

A study conducted by N. Jusuf *et al.* in 2020 reported that there are differences of microbiomes found in non-inflammatory and inflammatory lesions of acne vulgaris. *C. acnes*, *Staphylococcus epidermidis*, *Staphylococcus hominis*, *Staphylococcus haemolyticus*, *Leuconostoc mesentroides* and *Staphylococcus aureus* were isolated in all types of acne lesions but with significant quantitative differences [38]. On the other side, *Micrococcus luteus*, *Kocuria varians* and *Staphylococcus vitulinus* were present only in non-inflammatory lesions, while *Staphylococcus cohnii*, *Staphylococcus arlettae* and *Dermacoccus nishinomyaensis* were isolated only from inflammatory lesions [38].

Some coagulase-negative staphylococcal species like *Staphylococcus epidermidis* or *Staphy-*

*lococcus hominis* can be present in both healthy and acne skin [23]. In the last years, light has been shed upon the potential role of *Staphylococcus epidermidis* in the pathophysiology of acne [64]. Wang *et al.* (2016) observed that *Staphylococcus epidermidis* could control the proliferation of *C. acnes* by releasing succinic acid which inhibits the surface TLRs of keratinocytes and suppresses *C. acnes*-induced IL-6 [48].

Other studies have reported that *C. granulorum* is more abundant in the comedones and pustules and displays increased virulence phenotypes compared to *C. acnes* [65, 66].

*Malassezia* is one of the most abundant fungi of the skin. Song *et al.* (2011) and Numata *et al.* (2014) observed that *Malassezia restricta* and *Malassezia globosa* can be isolated from young acne patients [67, 68]. Moreover, Akaza *et al.* (2012) observed that the lipase activity of *Malassezia* is 100 times greater than the lipase activity of *C. acnes* [69]. *Malassezia* can hydrolyze triglycerides into free fatty acids which can interfere with the normal keratinization of hair follicular ducts [70, 71, 72, 73]. It can also chemoattract polymorphonuclear cells and promote the release of pro-inflammatory cytokines [70, 71, 72, 73].

*Demodex folliculorum* and *Demodex brevis* are ubiquitously found on the normal skin, especially in the pilosebaceous follicles of the face. *D. folliculorum* is found in the hair follicle, while *D. brevis* is found predominantly in the sebaceous glands. *Demodex* spp. may contribute to the development of acne by follicular obstruction, leading to distension, hyperkeratosis and inflammation [74, 75, 76].

### Antibiotic resistance of microorganisms associated with acne vulgaris

Antibiotic resistance is an important problem across medicine. Antibiotherapy, either topical or systemic, is frequently prescribed in acne vulgaris and may be associated with a variety of adverse reactions including bacterial resistance, skin dysbiosis, gut dysbiosis and others [77, 78, 79, 80, 81, 82, 83, 84]. Several reports highlight the

fact that antibiotic resistance of *C. acnes* is rising, including towards tetracycline-class antibiotics [77, 78, 79, 80, 81, 82, 83, 84]. Moreover, after long term antibiotherapy, it was observed that the skin microbiota is depleted especially in *Staphylococcus epidermidis* [77, 78, 79, 80, 81, 82, 83, 84].

## Conclusions

While the microbiome of each individual is unique and complex, researchers have observed the association of particular *C. acnes* strains with

inflammatory and non-inflammatory lesions of acne vulgaris. Moreover, skin microorganisms can display variable virulence patterns depending on external or host-related factors, alternating from beneficial to pathogenic. The complex interactions between different microorganisms as well as the host-microbiome interplay in acne vulgaris patients are currently under intense research. The results could contribute to the development of new therapies to modulate the proliferation of beneficial strains and promote skin homeostasis.

## Bibliography

1. Salvucci E. Microbiome, holobiont and the net of life. *Crit Rev Microbiol*. 2016;42(3):485-494.
2. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science*. 2012;336:1268-1273.
3. Lee YB, Byun EJ, Kim HS. Potential Role of the Microbiome in Acne: A Comprehensive Review. *J Clin Med*. 2019;8(7):987.
4. Grice EA, Segre JA. The skin microbiome [published correction appears in *Nat Rev Microbiol*. 2011 Aug;9(8):626]. *Nat Rev Microbiol*. 2011;9(4):244-253.
5. Guenin-Macé L, Morel JD, Doisne JM, et al. Dysregulation of tryptophan catabolism at the host-skin microbiota interface in hidradenitis suppurativa. *JCI Insight*. 2020;5(20):e140598.
6. Tay ASL, Li C, Nandi T, et al. Atopic dermatitis microbiomes stratify into ecologic dermatotypes enabling microbial virulence and disease. *J Allergy Clin Immunol*. 2020;S0091-6749(20)31399-3.
7. Yuan C, Ma Y, Wang Y, et al. Rosacea is associated with conjoined interactions between physical barrier of the skin and microorganisms: A pilot study. *J Clin Lab Anal*. 2020;34(9):e23363.
8. Pothmann A, Illing T, Wiegand C, et al. The Microbiome and Atopic Dermatitis: A Review. *Am J Clin Dermatol*. 2019 Dec;20(6):749-761.
9. Fyhrquist N, Muirhead G, Prast-Nielsen S, et al. Microbe-host interplay in atopic dermatitis and psoriasis. *Nat Commun*. 2019;10(1):4703.
10. Gerd P, Jansen T, Kligman AM. *Acne and Rosacea*. 3<sup>rd</sup> Edition, Ed. Berlin: Springer, 2000.
11. Dréno B, Dagnelie MA, Khammari A, Corvec S. The Skin Microbiome: A New Actor in Inflammatory Acne. *Am J Clin Dermatol*. 2020;21(Suppl 1):18-24.
12. Gao Z, Tseng CH, Pei Z, Blaser MJ. Molecular analysis of human forearm superficial skin bacterial biota. *Proc Natl Acad Sci U S A*. 2007;104(8):2927-2932.
13. Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. *Science*. 2009;324(5931):1190-1192.
14. Fitz-Gibbon S, Tomida S, Chiu BH, et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. *J Invest Dermatol*. 2013;133(9):2152-2160.
15. Faergemann J, Larkö O. The effect of UV-light on human skin microorganisms. *Acta Dermato-Venereologica*. 1987;67(1):69-72.
16. Fierer N, Hamady M, Lauber CL, Knight R. The influence of sex, handedness, and washing on the diversity of hand surface bacteria. *Proc Natl Acad Sci U S A*. 2008 Nov 18;105(46):17994-9.
17. McBride ME, Duncan WC, Knox JM. The environment and the microbial ecology of human skin. *Appl Environ Microbiol*. 1977;33(3):603-608.
18. Capone KA, Dowd SE, Stamatias GN, Nikolovski J. Diversity of the human skin microbiome early in life. *J Invest Dermatol*. 2011;131(10):2026-2032.
19. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Age-related changes in the resident bacterial flora of the human face. *J Invest Dermatol*. 1975;65(4):379-381.

20. Fierer N, Hamady M, Lauber CL, Knight R. The influence of sex, handedness, and washing on the diversity of hand surface bacteria. *Proc Natl Acad Sci U S A*. 2008;105(46):17994-17999.
21. Burkhart CG, Burkhart CN. Expanding the microcomedone theory and acne therapeutics: Propionibacterium acnes biofilm produces biological glue that holds corneocytes together to form plug. *J Am Acad Dermatol*. 2007;57(4):722-724.
22. O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. *Microbiome*. 2018;6(1):177.
23. Xu H, Li H. Acne, the Skin Microbiome, and Antibiotic Treatment. *Am J Clin Dermatol*. 2019;20(3):335-344.
24. McLaughlin J, Watterson S, Layton AM, et al. Propionibacterium acnes and Acne Vulgaris: New Insights from the Integration of Population Genetic, Multi-Omic, Biochemical and Host-Microbe Studies. *Microorganisms*. 2019;7(5):128.
25. Barnard E, Shi B, Kang D, Craft N, Li H. The balance of metagenomic elements shapes the skin microbiome in acne and health [published correction appears in *Sci Rep*. 2020 Apr 2;10(1):6037]. *Sci Rep*. 2016;6:39491.
26. Lomholt HB, Kilian M. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. *PLoS One*. 2010;5(8):e12277.
27. McDowell A, Barnard E, Nagy I, et al. An expanded multilocus sequence typing scheme for propionibacterium acnes: investigation of 'pathogenic', 'commensal' and antibiotic resistant strains. *PLoS One*. 2012;7(7):e41480.
28. Leyden JJ, McGinley KJ, Vowels B. Propionibacterium acnes colonization in acne and nonacne. *Dermatology*. 1998;196(1):55-58.
29. Perkins AC, Maglione J, Hillebrand GG, et al. Acne vulgaris in women: prevalence across the life span. *J Womens Health (Larchmt)*. 2012;21(2):223-230.
30. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older [published correction appears in *J Am Acad Dermatol*. 2008 May;58(5):874. Cafardi, Jennifer A [added]]. *J Am Acad Dermatol*. 2008;58(1):56-59.
31. Shu M, Wang Y, Yu J, et al. Fermentation of Propionibacterium acnes, a commensal bacterium in the human skin microbiome, as skin probiotics against methicillin-resistant Staphylococcus aureus. *PLoS One*. 2013;8(2):e55380.
32. Wang Y, Dai A, Huang S, et al. Propionic acid and its esterified derivative suppress the growth of methicillin-resistant Staphylococcus aureus USA300. *Benef Microbes*. 2014;5(2):161-168.
33. Rosberg-Cody E, Johnson MC, Fitzgerald GF, Ross PR, Stanton C. Heterologous expression of linoleic acid isomerase from Propionibacterium acnes and anti-proliferative activity of recombinant trans-10, cis-12 conjugated linoleic acid. *Microbiology (Reading)*. 2007;153(Pt 8):2483-2490.
34. Ou L, Wu Y, Ip C, Meng X, Hsu YC, Ip MM. Apoptosis induced by t10,c12-conjugated linoleic acid is mediated by an atypical endoplasmic reticulum stress response. *J Lipid Res*. 2008;49(5):985-994.
35. Ottaviani M, Camera E, Picardo M. Lipid mediators in acne. *Mediators Inflamm*. 2010;2010:858176.
36. Karoglan A, Paetzold B, Pereira de Lima J, et al. Safety and efficacy of topically applied selected Cutibacterium acnes strains over five weeks in patients with acne vulgaris: an open-label, pilot study. *Acta Derm Venereol*. 2019;99(13):1253-1257.
37. Tomida S, Nguyen L, Chiu BH, et al. Pan-genome and comparative genome analyses of propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome. *mBio*. 2013;4(3):e00003-e13.
38. Yusuf NK, Putra IB, Sari L. Differences of microbiomes found in non-inflammatory and inflammatory lesions of acne vulgaris. *Clin Cosmet Investig Dermatol*. 2020;13:773-780.
39. Barnard E, Liu J, Yankova E, et al. Strains of the Propionibacterium acnes type III lineage are associated with the skin condition progressive macular hypomelanosis. *Sci Rep*. 2016;6:31968.
40. Petersen RL, Scholz CF, Jensen A, et al. Propionibacterium acnes phylogenetic type III is associated with progressive macular hypomelanosis. *Eur J Microbiol Immunol (Bp)*. 2017;7(1):37-45.
41. Isard O, Knol AC, Ariès MF, et al. Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis and induces keratinocyte proliferation. *J Invest Dermatol*. 2011;131(1):59-66.
42. Dessinioti C, Katsambas AD. The role of Propionibacterium acnes in acne pathogenesis: facts and controversies. *Clin Dermatol*. 2010;28(1):2-7.
43. Scott DG, Cunliffe WJ, Gowland G. Activation of complement-a mechanism for the inflammation in acne. *Br J Dermatol*. 1979;101(3):315-320.
44. Terui T, Rokugo M, Kato T, Tagami H. Analysis of the proinflammatory property of epidermal cyst contents: chemotactic C5a anaphylatoxin generation. *Arch Dermatol Res*. 1989;281:31-34.
45. Jarrousse V, Castex-Rizzi N, Khammari A, et al. Modulation of integrins and filaggrin expression by Propionibacterium acnes extracts on keratinocytes. *Arch Dermatol Res*. 2007;299(9):441-447.

46. Kistowska M, Gehrke S, Jankovic D, et al. IL-1 $\beta$  drives inflammatory responses to *Propionibacterium acnes* in vitro and in vivo. *J Invest Dermatol.* 2014;134(3):677-685.
47. Alexeyev OA, Lundskog B, Ganceviciene R, et al. Pattern of tissue invasion by *Propionibacterium acnes* in acne vulgaris. *J Dermatol Sci.* 2012;67(1):63-66.
48. Wang Y, Kuo S, Shu M, et al. *Staphylococcus epidermidis* in the human skin microbiome mediates fermentation to inhibit the growth of *Propionibacterium acnes*: implications of probiotics in acne vulgaris. *Appl Microbiol Biotechnol.* 2014;98(1):411-424.
49. Xia X, Li Z, Liu K, et al. Staphylococcal LTA-Induced miR-143 Inhibits *Propionibacterium acnes*-Mediated Inflammatory Response in Skin. *J Invest Dermatol.* 2016;136(3):621-630.
50. Puhvel SM, Reisner RM. The production of hyaluronidase (hyaluronate lyase) by *Corynebacterium acnes*. *J Invest Dermatol.* 1972;58(2):66-70.
51. Hoeffler U. Enzymatic and hemolytic properties of *Propionibacterium acnes* and related bacteria. *J Clin Microbiol.* 1977;6(6):555-558.
52. Ingham E, Holland KT, Gowland G, Cunliffe WJ. Purification and partial characterization of an acid phosphatase (EC 3.1.3.2) produced by *Propionibacterium acnes*. *J Gen Microbiol.* 1980;118(1):59-65.
53. Liu PF, Nakatsuji T, Zhu W, et al. Passive immunoprotection targeting a secreted CAMP factor of *Propionibacterium acnes* as a novel immunotherapeutic for acne vulgaris. *Vaccine.* 2011;29(17):3230-3238.
54. McDowell A, Nagy I, Magyari M, et al The opportunistic pathogen *Propionibacterium acnes*: insights into typing, human disease, clonal diversification and CAMP factor evolution. *PLoS One.* 2013;8(9):e70897.
55. Lheure C, Grange PA, Ollagnier G, et al. TLR-2 Recognizes *Propionibacterium acnes* CAMP Factor 1 from Highly Inflammatory Strains. *PLoS One.* 2016;11(11):e0167237.
56. Platsidaki E, Dessinioti C. Recent advances in understanding *Propionibacterium acnes* (*Cutibacterium acnes*) in acne. *F1000Res.* 2018;7:F1000.
57. Nazipi S, Stødkilde-Jørgensen K, Scavenius C, Brüggemann H. The skin bacterium *Propionibacterium acnes* employs two variants of hyaluronate lyase with distinct properties. *Microorganisms.* 2017;5(3):57.
58. Sanford JA, O'Neill AM, Zouboulis CC, Gallo RL. Short-chain fatty acids from *Cutibacterium acnes* activate both a canonical and epigenetic inflammatory response in human sebocytes. *J Immunol.* 2019;202(6):1767-1776.
59. Zouboulis CC. *Propionibacterium acnes* and sebaceous lipogenesis: a love-hate relationship? *J Invest Dermatol.* 2009;129(9):2093-2096.
60. Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. *Br J Dermatol.* 2009;160(2):345-352.
61. Szöllösi AG, Oláh A, Bíró T, Tóth BI. Recent advances in the endocrinology of the sebaceous gland. *Dermatoendocrinol.* 2018;9(1):e1361576.
62. Alexeyev OA, Jahns AC. Sampling and detection of skin *Propionibacterium acnes*: current status. *Anaerobe.* 2012;18(5):479-483.
63. Mihai MM, Popa MI, Clatici VG, et al. *Propionibacterium acnes* and acne etiopathogenesis. *RojCED.* 2014; 1(1):78-80.
64. Claudel JP, Auffret N, Leccia MT, et al. *Staphylococcus epidermidis*: a potential new player in the physiopathology of acne? *Dermatology.* 2019;235(4):287-294.
65. Gehse M, Höffler U, Gloor M, Pulverer G. *Propionibacteria* in patients with acne vulgaris and in healthy persons. *Arch Dermatol Res.* 1983;275(2):100-104.
66. Whiteside JA, Voss JG. Incidence and lipolytic activity of *Propionibacterium acnes* (*Corynebacterium acnes* group I) and *Propionibacterium granulosum* (*Corynebacterium acnes* group II) in acne and in normal skin. *J Invest Dermatol.* 1973;60(2):94-97.
67. Song YC, Hahn HJ, Kim JY, et al. Epidemiologic study of *Malassezia* yeasts in acne patients by analysis of 26S rDNA PCR-RFLP. *Ann Dermatol.* 2011;23(3):321-328.
68. Numata S, Akamatsu H, Akaza N, et al. Analysis of facial skin-resident microbiota in Japanese acne patients. *Dermatology.* 2014;228(1):86-92.
69. Akaza N, Akamatsu H, Takeoka S, et al. *Malassezia globosa* tends to grow actively in summer conditions more than other cutaneous *Malassezia* species. *J Dermatol.* 2012;39(7):613-616.
70. Katsuta Y, Iida T, Inomata S, Denda M. Unsaturated fatty acids induce calcium influx into keratinocytes and cause abnormal differentiation of epidermis. *J Invest Dermatol.* 2005;124(5):1008-1013.
71. Webster GF. Inflammation in acne vulgaris. *J Am Acad Dermatol.* 1995;33(2 Pt 1):247-253.
72. Kesavan S, Walters CE, Holland KT, Ingham E. The effects of *Malassezia* on pro-inflammatory cytokine production by human peripheral blood mononuclear cells in vitro. *Med Mycol.* 1998;36(2):97-106.



73. Akaza N, Akamatsu H, Takeoka S, et al. Increased hydrophobicity in *Malassezia* species correlates with increased proinflammatory cytokine expression in human keratinocytes. *Med Mycol.* 2012;50(8):802-810.
74. Zhao YE, Hu L, Wu LP, Ma JX. A meta-analysis of association between acne vulgaris and *Demodex* infestation. *J Zhejiang Univ Sci B.* 2012;13(3):192-202.
75. Lacey N, Ní Raghallaigh S, Powell FC. *Demodex* mites—commensals, parasites or mutualistic organisms? *Dermatology.* 2011;222(2):128-130.
76. Aktaş Karabay E, Aksu Çerman A. *Demodex folliculorum* infestations in common facial dermatoses: acne vulgaris, rosacea, seborrheic dermatitis. *An Bras Dermatol.* 2020;95(2):187-193.
77. Cooper AJ. Systematic review of *Propionibacterium acnes* resistance to systemic antibiotics. *Med J Aust.* 1998;169(5):259-261.
78. Walsh TR, Efthimiou J, Dréno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. *Lancet Infect Dis.* 2016;16(3):e23-e33.
79. Del Rosso JQ, Zeichner JA. The clinical relevance of antibiotic resistance: thirteen principles that every dermatologist needs to consider when prescribing antibiotic therapy. *Dermatol Clin.* 2016;34(2):167-173.
80. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant *Propionibacterium acnes* isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. *Br J Dermatol.* 2001;144(2):339-346.
81. Delost GR, Delost ME, Armile J, Lloyd J. *Staphylococcus aureus* carriage rates and antibiotic resistance patterns in patients with acne vulgaris. *J Am Acad Dermatol.* 2016;74(4):673-678.
82. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. *Arch Dermatol.* 2003;139(4):467-471.
83. Margolis DJ, Fanelli M, Kupperman E, et al. Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study. *Arch Dermatol.* 2012;148(3):326-332.
84. Henry CS, Broadbelt LJ, Hatzimanikatis V. Thermodynamics-based metabolic flux analysis. *Biophys J.* 2007;92(5):1792-1805.

Conflict of interest  
NONE DECLARED

Correspondance address: Liliana Gabriela Popa  
Str. Dionisie Lupu, No. 37, 020021, District 2,  
Bucharest, Romania  
E-mail: lilidiaconu@yahoo.com